|
gptkbp:instanceOf
|
gptkb:chemical_compound
recreational drug
|
|
gptkbp:actsOn
|
stimulant
monoamine releasing agent
|
|
gptkbp:aroma
|
fishy
|
|
gptkbp:boilingPoint
|
203°C
|
|
gptkbp:CASNumber
|
300-62-9
|
|
gptkbp:chemicalFormula
|
C9H13N
|
|
gptkbp:color
|
colorless to pale yellow
|
|
gptkbp:contains_functional_group
|
amphetamine
phenyl
|
|
gptkbp:effect
|
stimulant
anorectic
euphoriant
sympathomimetic
|
|
gptkbp:eliminationHalfLife
|
9-14 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
gptkb:Lazăr_Edeleanu
|
|
gptkbp:hasStreet
|
gptkb:foundation
paste
speed
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Base amphetamine
|
|
gptkbp:is_base_form_of
|
gptkb:amphetamine_hydrochloride
amphetamine sulfate
|
|
gptkbp:IUPACName
|
1-phenylpropan-2-amine
|
|
gptkbp:legalStatus
|
controlled substance (varies by country)
|
|
gptkbp:meltingPoint
|
11°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
135.21 g/mol
|
|
gptkbp:neurotransmitter
|
dopamine
norepinephrine
serotonin
|
|
gptkbp:predecessor
|
gptkb:MDMA
gptkb:amphetamine_hydrochloride
amphetamine
amphetamine sulfate
|
|
gptkbp:PubChem_CID
|
3007
CHEMBL405
DB00182
|
|
gptkbp:riskFactor
|
addiction
psychosis
insomnia
cardiovascular side effects
|
|
gptkbp:routeOfAdministration
|
oral
inhalation
intravenous
intranasal
|
|
gptkbp:solubility
|
soluble in organic solvents
insoluble in water (base form)
|
|
gptkbp:UNII
|
U3C085WY1Q
|
|
gptkbp:usedFor
|
treatment of ADHD (as salt forms)
treatment of narcolepsy (as salt forms)
|
|
gptkbp:year_of_first_synthesis
|
1887
|
|
gptkbp:bfsParent
|
gptkb:Base_(drug_culture)
|
|
gptkbp:bfsLayer
|
5
|